Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer : Medical Ethics Committee of Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University
High risk prostate cancer (PCa) had worse outcomes on radical treatment results, short-time oncological results, even cancer-specific survival, than those low or mediate risk PCa. Neoadjuvant treatment before radical prostatectomy had been proven to get some benefits on peri-operation results, especially on reduction of tumor volume and minimization of biochemical recurrence. This study will evaluate the efficacy and safety of androgen deprivation therapy (ADT) with abiraterone in neoadjuvant therapy for surgically resectable high-risk or very high-risk PCa..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
ClinicalTrials.gov - (2022) vom: 16. Dez. Zur Gesamtaufnahme - year:2022 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: April 22, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 21, 2022, Last updated: December 21, 2022 |
---|
Study ID: |
NCT04356430 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG003367290 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG003367290 | ||
003 | DE-627 | ||
005 | 20230425210419.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2022 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG003367290 | ||
035 | |a (UBBS_Klinische_Studien)NCT04356430 | ||
035 | |a (UBBS_Klinische_Studien)IUNU-PC-101 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer |b Medical Ethics Committee of Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: April 22, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 21, 2022, Last updated: December 21, 2022 | ||
520 | |a High risk prostate cancer (PCa) had worse outcomes on radical treatment results, short-time oncological results, even cancer-specific survival, than those low or mediate risk PCa. Neoadjuvant treatment before radical prostatectomy had been proven to get some benefits on peri-operation results, especially on reduction of tumor volume and minimization of biochemical recurrence. This study will evaluate the efficacy and safety of androgen deprivation therapy (ADT) with abiraterone in neoadjuvant therapy for surgically resectable high-risk or very high-risk PCa. | ||
650 | 2 | |a Prostatic Neoplasms | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Active, not recruiting | |
650 | 4 | |a Phase: Phase 2 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2022) vom: 16. Dez. |
773 | 1 | 8 | |g year:2022 |g day:16 |g month:12 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04356430 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2022 |b 16 |c 12 |